Grace Therapeutics Posts $15.8M Q1 Loss, Extends Cash Runway to 2028
GRCE is trading near its 52-week low of $1.79 (14% above the low).
Summary
A $15.8 million Q1 loss, including a $13.5 million impairment of deprioritized programs, was offset by a cash runway extension to 2028 and progress on a dual-source manufacturing strategy for GTx-104.
Key Events · Earnings and Guidance · GRCE
-
Q1 FY2027 Net Loss of $15.8M
For the quarter ended June 30, 2026, the net loss widened to $15.8 million, or $0.91 per share, from $3.4 million, or $0.21 per share, a year earlier. The jump was primarily due to a $13.5 million impairment of IPR&D related to GTx-101 and GTx-102.
-
Cash Runway Extended to 2028
Cash and cash equivalents totaled $22.2 million as of August 11, 2026. Management believes this is sufficient to sustain planned operations, including addressing CRL items, through the end of calendar 2028.
-
Dual-Source Manufacturing Strategy
Technology transfer to a second U.S.-based contract manufacturer is underway. NDA resubmission timing will depend on which manufacturing site reaches readiness first: the U.S. facility requires 12 months of stability data, while the current contract manufacturer could be faster if it remediates FDA compliance issues sooner.
-
No Impairment for GTx-104
After the FDA's Complete Response Letter, the company assessed GTx-104 IPR&D and determined its fair value exceeds the carrying amount, so no impairment charge was recorded for the quarter.
Analysis · GRCE · Life Sciences
A $13.5 million impairment tied to the deprioritized GTx-101 and GTx-102 programs drove the company to a $15.8 million quarterly loss. Cash stood at $22.2 million as of August 11, 2026, which management says funds operations through the end of calendar 2028. To support its lead asset, the company is advancing a dual-source manufacturing strategy for GTx-104, with technology transfer to a second U.S.-based contract manufacturer already in motion. Following the FDA's Complete Response Letter, no impairment was required for GTx-104 IPR&D, underscoring confidence in the asset's value.
At the time of this filing, GRCE was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.2M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.